10x Genomics Partners with Cleveland Clinic on Bladder Cancer Biomarker Study Using Flex Apex, Xenium
TXG•10x Genomics initiated a multi-year collaboration with Cleveland Clinic to identify biomarkers predicting antibody-drug conjugate response in bladder cancer using its Flex Apex and Xenium platforms, with plans to add the Atera platform. The study will combine single-cell transcriptomics and spatial gene expression to map microenvironments and support diagnostic development.
1. Collaboration Overview
10x Genomics and Cleveland Clinic launched a multi-year collaboration to identify biomarkers predictive of antibody-drug conjugate response in advanced bladder cancer using 10x’s single-cell and spatial technologies.
2. Research Methodology
The initial phase will profile tumor samples from patients treated with antibody-drug conjugates and immunotherapies using Flex Apex and Xenium platforms, with plans to incorporate the Atera platform for expanded multimodal analysis.
3. Expected Outcomes and Implications
Researchers will integrate single-cell transcriptomics, spatial gene expression and protein data to map tumor microenvironments and therapeutic target expression, aiming to support development of diagnostic applications and improve treatment decision-making in oncology.
